BRCA mutation (English Wikipedia)

Iodice S, Barile M, Rotmensz N, Feroce I, Bonanni B, Radice P, et al. (August 2010). "Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis". European Journal of Cancer. 46 (12): 2275–2284. doi:10.1016/j.ejca.2010.04.018. PMID 20537530.
Lu KH, Berchuck A, Kauff ND (2013). "Hereditary gynecologic cancers". In Barakat RD, Berchuck A, Markman M, Randall ME (eds.). Principles and practice of gynecologic oncology (6th ed.). Philadelphia: Lippincott Williams & Wilkins. ISBN 978-1-4698-3148-0.
Isaacs C, Fletcher SW, Peskin BN (May 2013). Hayes DF, Duda RB (eds.). "Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations". Waltham, Mass.: UpToDate. Retrieved 13 June 2013.
PDQ Cancer Genetics Editorial Board (7 June 2013). "PDQ Genetics of breast and ovarian cancer (Health professional version)". Bethesda, Md.: National Cancer Institute. Retrieved 13 June 2013.

cancer.gov

"BRCA1 and BRCA2: Cancer Risk and Genetic Testing". National Cancer Institute. 29 May 2009.
Iodice S, Barile M, Rotmensz N, Feroce I, Bonanni B, Radice P, et al. (August 2010). "Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis". European Journal of Cancer. 46 (12): 2275–2284. doi:10.1016/j.ejca.2010.04.018. PMID 20537530.
Lu KH, Berchuck A, Kauff ND (2013). "Hereditary gynecologic cancers". In Barakat RD, Berchuck A, Markman M, Randall ME (eds.). Principles and practice of gynecologic oncology (6th ed.). Philadelphia: Lippincott Williams & Wilkins. ISBN 978-1-4698-3148-0.
Isaacs C, Fletcher SW, Peskin BN (May 2013). Hayes DF, Duda RB (eds.). "Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations". Waltham, Mass.: UpToDate. Retrieved 13 June 2013.
PDQ Cancer Genetics Editorial Board (7 June 2013). "PDQ Genetics of breast and ovarian cancer (Health professional version)". Bethesda, Md.: National Cancer Institute. Retrieved 13 June 2013.

cnn.com

edition.cnn.com

Yan H (14 May 2013). "What's the gene that led to Angelina Jolie's double mastectomy?". Health. CNN.
"ACLU sues over patents on breast cancer genes". CNN. Archived from the original on 15 May 2009. Retrieved 14 May 2009.

doi.org

Weitzel JN, Lagos VI, Cullinane CA, Gambol PJ, Culver JO, Blazer KR, et al. (June 2007). "Limited family structure and BRCA gene mutation status in single cases of breast cancer". JAMA. 297 (23): 2587–2595. doi:10.1001/jama.297.23.2587. PMID 17579227.
Chen S, Parmigiani G (April 2007). "Meta-analysis of BRCA1 and BRCA2 penetrance". Journal of Clinical Oncology. 25 (11): 1329–1333. doi:10.1200/JCO.2006.09.1066. PMC 2267287. PMID 17416853.
Veronesi A, de Giacomi C, Magri MD, Lombardi D, Zanetti M, Scuderi C, et al. (July 2005). "Familial breast cancer: characteristics and outcome of BRCA 1-2 positive and negative cases". BMC Cancer. 5: 70. doi:10.1186/1471-2407-5-70. PMC 1184063. PMID 15996267.
Budroni M, Cesaraccio R, Coviello V, Sechi O, Pirino D, Cossu A, et al. (February 2009). "Role of BRCA2 mutation status on overall survival among breast cancer patients from Sardinia". BMC Cancer. 9: 62. doi:10.1186/1471-2407-9-62. PMC 2653541. PMID 19232099.
Verhoog LC, Brekelmans CT, Seynaeve C, van den Bosch LM, Dahmen G, van Geel AN, et al. (January 1998). "Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1". Lancet. 351 (9099): 316–321. doi:10.1016/S0140-6736(97)07065-7. PMID 9652611. S2CID 38655517.
O'Malley DM, Krivak TC, Kabil N, Munley J, Moore KN (July 2023). "PARP Inhibitors in Ovarian Cancer: A Review". Targeted Oncology. 18 (4): 471–503. doi:10.1007/s11523-023-00970-w. PMC 10344972. PMID 37268756.
Kurian AW, Sigal BM, Plevritis SK (January 2010). "Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers". Journal of Clinical Oncology. 28 (2): 222–231. doi:10.1200/JCO.2009.22.7991. PMC 2815712. PMID 19996031.
Friedenson B (August 2007). "The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers". BMC Cancer. 7: 152. doi:10.1186/1471-2407-7-152. PMC 1959234. PMID 17683622.
Fishman A (October 2010). "The effects of parity, breastfeeding, and infertility treatment on the risk of hereditary breast and ovarian cancer: a review". International Journal of Gynecological Cancer. 20 (11 Suppl 2): S31–S33. doi:10.1111/IGC.0b013e3181f60d4d. PMID 20975359. S2CID 42755864.
Pal T, Keefe D, Sun P, Narod SA (April 2010). "Fertility in women with BRCA mutations: a case-control study". Fertility and Sterility. 93 (6): 1805–1808. doi:10.1016/j.fertnstert.2008.12.052. PMID 19200971.
Broer SL, Broekmans FJ, Laven JS, Fauser BC (2014). "Anti-Müllerian hormone: ovarian reserve testing and its potential clinical implications". Human Reproduction Update. 20 (5): 688–701. doi:10.1093/humupd/dmu020. PMID 24821925.
Oktay K, Kim JY, Barad D, Babayev SN (January 2010). "Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks". Journal of Clinical Oncology. 28 (2): 240–244. doi:10.1200/JCO.2009.24.2057. PMC 3040011. PMID 19996028.
Moslehi R, Singh R, Lessner L, Friedman JM (March–April 2010). "Impact of BRCA mutations on female fertility and offspring sex ratio". American Journal of Human Biology. 22 (2): 201–205. doi:10.1002/ajhb.20978. PMC 3739697. PMID 19642207.
Balmaña J, Díez O, Campos B, Majewski M, Sanz J, Alonso C, et al. (August 2005). "Sex ratio distortion in offspring of families with BRCA1 or BRCA2 mutant alleles: an ascertainment bias phenomenon?". Breast Cancer Research and Treatment. 92 (3): 273–277. doi:10.1007/s10549-005-3377-x. PMID 16155798. S2CID 21830848.
Agnese DM (March 2006). "Battle of the BRCA1/BRCA2 (offspring) sex ratios: truth or consequences". Journal of Medical Genetics. 43 (3): 201–202. doi:10.1136/jmg.2004.028977. PMC 2563236. PMID 16033919.
Kotsopoulos J, Lubinski J, Salmena L, Lynch HT, Kim-Sing C, Foulkes WD, et al. (March 2012). "Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers". Breast Cancer Research. 14 (2): R42. doi:10.1186/bcr3138. PMC 3446376. PMID 22405187.
Sawyer SL, Tian L, Kähkönen M, Schwartzentruber J, Kircher M, Majewski J, et al. (February 2015). "Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype". Cancer Discovery. 5 (2): 135–142. doi:10.1158/2159-8290.CD-14-1156. PMC 4320660. PMID 25472942.
Maxwell KN, Patel V, Nead KT, Merrill S, Clark D, Jiang Q, et al. (January 2023). "Fanconi anemia caused by biallelic inactivation of BRCA2 can present with an atypical cancer phenotype in adulthood". Clinical Genetics. 103 (1): 119–124. doi:10.1111/cge.14231. PMC 9742260. PMID 36089892.
Yoshida K, Miki Y (November 2004). "Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage". Cancer Science. 95 (11): 866–871. doi:10.1111/j.1349-7006.2004.tb02195.x. PMC 11159131. PMID 15546503. S2CID 24297965.
Cui J, Antoniou AC, Dite GS, Southey MC, Venter DJ, Easton DF, et al. (February 2001). "After BRCA1 and BRCA2-what next? Multifactorial segregation analyses of three-generation, population-based Australian families affected by female breast cancer". American Journal of Human Genetics. 68 (2): 420–431. doi:10.1086/318187. PMC 1235275. PMID 11133358.
Greenberg RA (September 2006). "BRCA mutations and childhood cancer". Cancer Biology & Therapy. 5 (9): 1103–1104. doi:10.4161/cbt.5.9.3370. PMC 2703724. PMID 17012842.
Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, et al. (August 2019). "Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement". JAMA. 322 (7): 652–665. doi:10.1001/jama.2019.10987. PMID 31429903.
Frank TS (2002). "Hereditary Risk of Breast and Ovarian Cancer: BRCA1 and BRCA2". Encyclopedia of Cancer: 381–385. doi:10.1016/b0-12-227555-1/00090-3. ISBN 978-0-12-227555-5.
Rosenberg SM, Ruddy KJ, Tamimi RM, Gelber S, Schapira L, Come S, et al. (June 2016). "BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer". JAMA Oncology. 2 (6): 730–736. doi:10.1001/jamaoncol.2015.5941. PMC 5002892. PMID 26867710.
Kukafka R, Pan S, Silverman T, Zhang T, Chung WK, Terry MB, Fleck E, Younge RG, Trivedi MS, McGuinness JE, He T, Dimond J, Crew KD (18 July 2022). "Patient and Clinician Decision Support to Increase Genetic Counseling for Hereditary Breast and Ovarian Cancer Syndrome in Primary Care". JAMA Network Open. 5 (7). American Medical Association (AMA): e2222092. doi:10.1001/jamanetworkopen.2022.22092. ISSN 2574-3805. PMC 9294997.
Pijpe A, Andrieu N, Easton DF, Kesminiene A, Cardis E, Noguès C, et al. (September 2012). "Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK)". BMJ. 345: e5660. doi:10.1136/bmj.e5660. PMC 3435441. PMID 22956590.
Lynch HT, Casey MJ, Snyder CL, Bewtra C, Lynch JF, Butts M, Godwin AK (April 2009). "Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management". Molecular Oncology. 3 (2): 97–137. doi:10.1016/j.molonc.2009.02.004. PMC 2778287. PMID 19383374.
Moorman PG, Havrilesky LJ, Gierisch JM, Coeytaux RR, Lowery WJ, Peragallo Urrutia R, et al. (November 2013). "Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis". Journal of Clinical Oncology. 31 (33): 4188–4198. doi:10.1200/JCO.2013.48.9021. PMID 24145348.
Iodice S, Barile M, Rotmensz N, Feroce I, Bonanni B, Radice P, et al. (August 2010). "Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis". European Journal of Cancer. 46 (12): 2275–2284. doi:10.1016/j.ejca.2010.04.018. PMID 20537530.
Lu KH, Berchuck A, Kauff ND (2013). "Hereditary gynecologic cancers". In Barakat RD, Berchuck A, Markman M, Randall ME (eds.). Principles and practice of gynecologic oncology (6th ed.). Philadelphia: Lippincott Williams & Wilkins. ISBN 978-1-4698-3148-0.
Isaacs C, Fletcher SW, Peskin BN (May 2013). Hayes DF, Duda RB (eds.). "Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations". Waltham, Mass.: UpToDate. Retrieved 13 June 2013.
PDQ Cancer Genetics Editorial Board (7 June 2013). "PDQ Genetics of breast and ovarian cancer (Health professional version)". Bethesda, Md.: National Cancer Institute. Retrieved 13 June 2013.
Cibula D, Zikan M, Dusek L, Majek O (August 2011). "Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis". Expert Review of Anticancer Therapy. 11 (8): 1197–1207. doi:10.1586/era.11.38. PMID 21916573. S2CID 31012428.
Pruthi S, Gostout BS, Lindor NM (December 2010). "Identification and Management of Women With BRCA Mutations or Hereditary Predisposition for Breast and Ovarian Cancer". Mayo Clinic Proceedings. 85 (12): 1111–1120. doi:10.4065/mcp.2010.0414. PMC 2996153. PMID 21123638.
Burke W, Daly M, Garber J, Botkin J, Kahn MJ, Lynch P, et al. (March 1997). "Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium". JAMA. 277 (12): 997–1003. doi:10.1001/jama.1997.03540360065034. PMID 9091675.
Kwon JS, Tinker A, Pansegrau G, McAlpine J, Housty M, McCullum M, Gilks CB (January 2013). "Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers". Obstetrics and Gynecology. 121 (1): 14–24. doi:10.1097/AOG.0b013e3182783c2f. PMID 23232752. S2CID 41081248.
"Earlier decisions on breast and ovarian surgery reduce cancer in women at high risk". NIHR Evidence (Plain English summary). National Institute for Health and Care Research. 7 December 2021. doi:10.3310/alert_48318. S2CID 263487127.
Marcinkute R, Woodward ER, Gandhi A, Howell S, Crosbie EJ, Wissely J, et al. (February 2022). "Uptake and efficacy of bilateral risk reducing surgery in unaffected female BRCA1 and BRCA2 carriers". Journal of Medical Genetics. 59 (2): 133–140. doi:10.1136/jmedgenet-2020-107356. PMID 33568438. S2CID 231876899.
Stadler ZK, Kauff ND (January 2010). "Weighing options for cancer risk reduction in carriers of BRCA1 and BRCA2 mutations". Journal of Clinical Oncology. 28 (2): 189–191. doi:10.1200/JCO.2009.25.6875. PMID 19996025.
Jeffers L, Reid J, Fitzsimons D, Morrison PJ, Dempster M (October 2019). "Interventions to improve psychosocial well-being in female BRCA-mutation carriers following risk-reducing surgery". The Cochrane Database of Systematic Reviews. 2019 (10): CD012894. doi:10.1002/14651858.cd012894.pub2. PMC 6784162. PMID 31595976.
King MC, Marks JH, Mandell JB (October 2003). "Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2". Science. 302 (5645): 643–646. Bibcode:2003Sci...302..643K. doi:10.1126/science.1088759. PMID 14576434. S2CID 33441900.
Huttley GA, Easteal S, Southey MC, Tesoriero A, Giles GG, McCredie MR, et al. (August 2000). "Adaptive evolution of the tumour suppressor BRCA1 in humans and chimpanzees. Australian Breast Cancer Family Study". Nature Genetics. 25 (4): 410–413. doi:10.1038/78092. PMID 10932184. S2CID 10004449.
Cook-Deegan R, DeRienzo C, Carbone J, Chandrasekharan S, Heaney C, Conover C (April 2010). "Impact of gene patents and licensing practices on access to genetic testing for inherited susceptibility to cancer: comparing breast and ovarian cancers with colon cancers". Genetics in Medicine. 12 (4 Suppl): S15–S38. doi:10.1097/GIM.0b013e3181d5a67b. PMC 3047448. PMID 20393305.
Benowitz S (January 2003). "European groups oppose Myriad's latest patent on BRCA1". Journal of the National Cancer Institute. 95 (1): 8–9. doi:10.1093/jnci/95.1.8. PMID 12509391.

genomicslawreport.com

Conley J, Vorhous D, Cook-Deegan J (1 March 2011). "How Will Myriad Respond to the Next Generation of BRCA Testing?". Robinson, Bradshaw, and Hinson. Retrieved 9 December 2012.

gosh.nhs.uk

"Referral guidelines - cancer genetics". www.gosh.nhs.uk. Retrieved 21 February 2016.

harvard.edu

ui.adsabs.harvard.edu

King MC, Marks JH, Mandell JB (October 2003). "Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2". Science. 302 (5645): 643–646. Bibcode:2003Sci...302..643K. doi:10.1126/science.1088759. PMID 14576434. S2CID 33441900.

manchester.ac.uk

pure.manchester.ac.uk

Marcinkute R, Woodward ER, Gandhi A, Howell S, Crosbie EJ, Wissely J, et al. (February 2022). "Uptake and efficacy of bilateral risk reducing surgery in unaffected female BRCA1 and BRCA2 carriers". Journal of Medical Genetics. 59 (2): 133–140. doi:10.1136/jmedgenet-2020-107356. PMID 33568438. S2CID 231876899.

myriad.com

investor.myriad.com

Myriad Investor Page—see "Myriad at a glance" Archived 18 October 2012 at the Wayback Machine accessed October 2012

nih.gov

pubmed.ncbi.nlm.nih.gov

Petrucelli N, Daly MB, Pal T (September 1998). "BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer". In Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJ, Gripp KW, Amemiya A, editors (eds.). GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle. PMID 20301425.
Weitzel JN, Lagos VI, Cullinane CA, Gambol PJ, Culver JO, Blazer KR, et al. (June 2007). "Limited family structure and BRCA gene mutation status in single cases of breast cancer". JAMA. 297 (23): 2587–2595. doi:10.1001/jama.297.23.2587. PMID 17579227.
Chen S, Parmigiani G (April 2007). "Meta-analysis of BRCA1 and BRCA2 penetrance". Journal of Clinical Oncology. 25 (11): 1329–1333. doi:10.1200/JCO.2006.09.1066. PMC 2267287. PMID 17416853.
Veronesi A, de Giacomi C, Magri MD, Lombardi D, Zanetti M, Scuderi C, et al. (July 2005). "Familial breast cancer: characteristics and outcome of BRCA 1-2 positive and negative cases". BMC Cancer. 5: 70. doi:10.1186/1471-2407-5-70. PMC 1184063. PMID 15996267.
Budroni M, Cesaraccio R, Coviello V, Sechi O, Pirino D, Cossu A, et al. (February 2009). "Role of BRCA2 mutation status on overall survival among breast cancer patients from Sardinia". BMC Cancer. 9: 62. doi:10.1186/1471-2407-9-62. PMC 2653541. PMID 19232099.
Verhoog LC, Brekelmans CT, Seynaeve C, van den Bosch LM, Dahmen G, van Geel AN, et al. (January 1998). "Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1". Lancet. 351 (9099): 316–321. doi:10.1016/S0140-6736(97)07065-7. PMID 9652611. S2CID 38655517.
O'Malley DM, Krivak TC, Kabil N, Munley J, Moore KN (July 2023). "PARP Inhibitors in Ovarian Cancer: A Review". Targeted Oncology. 18 (4): 471–503. doi:10.1007/s11523-023-00970-w. PMC 10344972. PMID 37268756.
Kurian AW, Sigal BM, Plevritis SK (January 2010). "Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers". Journal of Clinical Oncology. 28 (2): 222–231. doi:10.1200/JCO.2009.22.7991. PMC 2815712. PMID 19996031.
Friedenson B (June 2005). "BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian". MedGenMed. 7 (2): 60. PMC 1681605. PMID 16369438.
Friedenson B (August 2007). "The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers". BMC Cancer. 7: 152. doi:10.1186/1471-2407-7-152. PMC 1959234. PMID 17683622.
Fishman A (October 2010). "The effects of parity, breastfeeding, and infertility treatment on the risk of hereditary breast and ovarian cancer: a review". International Journal of Gynecological Cancer. 20 (11 Suppl 2): S31–S33. doi:10.1111/IGC.0b013e3181f60d4d. PMID 20975359. S2CID 42755864.
Pal T, Keefe D, Sun P, Narod SA (April 2010). "Fertility in women with BRCA mutations: a case-control study". Fertility and Sterility. 93 (6): 1805–1808. doi:10.1016/j.fertnstert.2008.12.052. PMID 19200971.
Broer SL, Broekmans FJ, Laven JS, Fauser BC (2014). "Anti-Müllerian hormone: ovarian reserve testing and its potential clinical implications". Human Reproduction Update. 20 (5): 688–701. doi:10.1093/humupd/dmu020. PMID 24821925.
Oktay K, Kim JY, Barad D, Babayev SN (January 2010). "Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks". Journal of Clinical Oncology. 28 (2): 240–244. doi:10.1200/JCO.2009.24.2057. PMC 3040011. PMID 19996028.
Moslehi R, Singh R, Lessner L, Friedman JM (March–April 2010). "Impact of BRCA mutations on female fertility and offspring sex ratio". American Journal of Human Biology. 22 (2): 201–205. doi:10.1002/ajhb.20978. PMC 3739697. PMID 19642207.
Balmaña J, Díez O, Campos B, Majewski M, Sanz J, Alonso C, et al. (August 2005). "Sex ratio distortion in offspring of families with BRCA1 or BRCA2 mutant alleles: an ascertainment bias phenomenon?". Breast Cancer Research and Treatment. 92 (3): 273–277. doi:10.1007/s10549-005-3377-x. PMID 16155798. S2CID 21830848.
Agnese DM (March 2006). "Battle of the BRCA1/BRCA2 (offspring) sex ratios: truth or consequences". Journal of Medical Genetics. 43 (3): 201–202. doi:10.1136/jmg.2004.028977. PMC 2563236. PMID 16033919.
Kotsopoulos J, Lubinski J, Salmena L, Lynch HT, Kim-Sing C, Foulkes WD, et al. (March 2012). "Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers". Breast Cancer Research. 14 (2): R42. doi:10.1186/bcr3138. PMC 3446376. PMID 22405187.
Sawyer SL, Tian L, Kähkönen M, Schwartzentruber J, Kircher M, Majewski J, et al. (February 2015). "Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype". Cancer Discovery. 5 (2): 135–142. doi:10.1158/2159-8290.CD-14-1156. PMC 4320660. PMID 25472942.
Maxwell KN, Patel V, Nead KT, Merrill S, Clark D, Jiang Q, et al. (January 2023). "Fanconi anemia caused by biallelic inactivation of BRCA2 can present with an atypical cancer phenotype in adulthood". Clinical Genetics. 103 (1): 119–124. doi:10.1111/cge.14231. PMC 9742260. PMID 36089892.
Yoshida K, Miki Y (November 2004). "Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage". Cancer Science. 95 (11): 866–871. doi:10.1111/j.1349-7006.2004.tb02195.x. PMC 11159131. PMID 15546503. S2CID 24297965.
Cui J, Antoniou AC, Dite GS, Southey MC, Venter DJ, Easton DF, et al. (February 2001). "After BRCA1 and BRCA2-what next? Multifactorial segregation analyses of three-generation, population-based Australian families affected by female breast cancer". American Journal of Human Genetics. 68 (2): 420–431. doi:10.1086/318187. PMC 1235275. PMID 11133358.
Greenberg RA (September 2006). "BRCA mutations and childhood cancer". Cancer Biology & Therapy. 5 (9): 1103–1104. doi:10.4161/cbt.5.9.3370. PMC 2703724. PMID 17012842.
Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, et al. (August 2019). "Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement". JAMA. 322 (7): 652–665. doi:10.1001/jama.2019.10987. PMID 31429903.
Rosenberg SM, Ruddy KJ, Tamimi RM, Gelber S, Schapira L, Come S, et al. (June 2016). "BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer". JAMA Oncology. 2 (6): 730–736. doi:10.1001/jamaoncol.2015.5941. PMC 5002892. PMID 26867710.
Pijpe A, Andrieu N, Easton DF, Kesminiene A, Cardis E, Noguès C, et al. (September 2012). "Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK)". BMJ. 345: e5660. doi:10.1136/bmj.e5660. PMC 3435441. PMID 22956590.
Lynch HT, Casey MJ, Snyder CL, Bewtra C, Lynch JF, Butts M, Godwin AK (April 2009). "Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management". Molecular Oncology. 3 (2): 97–137. doi:10.1016/j.molonc.2009.02.004. PMC 2778287. PMID 19383374.
Moorman PG, Havrilesky LJ, Gierisch JM, Coeytaux RR, Lowery WJ, Peragallo Urrutia R, et al. (November 2013). "Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis". Journal of Clinical Oncology. 31 (33): 4188–4198. doi:10.1200/JCO.2013.48.9021. PMID 24145348.
Iodice S, Barile M, Rotmensz N, Feroce I, Bonanni B, Radice P, et al. (August 2010). "Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis". European Journal of Cancer. 46 (12): 2275–2284. doi:10.1016/j.ejca.2010.04.018. PMID 20537530.
Lu KH, Berchuck A, Kauff ND (2013). "Hereditary gynecologic cancers". In Barakat RD, Berchuck A, Markman M, Randall ME (eds.). Principles and practice of gynecologic oncology (6th ed.). Philadelphia: Lippincott Williams & Wilkins. ISBN 978-1-4698-3148-0.
Isaacs C, Fletcher SW, Peskin BN (May 2013). Hayes DF, Duda RB (eds.). "Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations". Waltham, Mass.: UpToDate. Retrieved 13 June 2013.
PDQ Cancer Genetics Editorial Board (7 June 2013). "PDQ Genetics of breast and ovarian cancer (Health professional version)". Bethesda, Md.: National Cancer Institute. Retrieved 13 June 2013.
Cibula D, Zikan M, Dusek L, Majek O (August 2011). "Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis". Expert Review of Anticancer Therapy. 11 (8): 1197–1207. doi:10.1586/era.11.38. PMID 21916573. S2CID 31012428.
Pruthi S, Gostout BS, Lindor NM (December 2010). "Identification and Management of Women With BRCA Mutations or Hereditary Predisposition for Breast and Ovarian Cancer". Mayo Clinic Proceedings. 85 (12): 1111–1120. doi:10.4065/mcp.2010.0414. PMC 2996153. PMID 21123638.
Burke W, Daly M, Garber J, Botkin J, Kahn MJ, Lynch P, et al. (March 1997). "Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium". JAMA. 277 (12): 997–1003. doi:10.1001/jama.1997.03540360065034. PMID 9091675.
Kwon JS, Tinker A, Pansegrau G, McAlpine J, Housty M, McCullum M, Gilks CB (January 2013). "Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers". Obstetrics and Gynecology. 121 (1): 14–24. doi:10.1097/AOG.0b013e3182783c2f. PMID 23232752. S2CID 41081248.
Marcinkute R, Woodward ER, Gandhi A, Howell S, Crosbie EJ, Wissely J, et al. (February 2022). "Uptake and efficacy of bilateral risk reducing surgery in unaffected female BRCA1 and BRCA2 carriers". Journal of Medical Genetics. 59 (2): 133–140. doi:10.1136/jmedgenet-2020-107356. PMID 33568438. S2CID 231876899.
Stadler ZK, Kauff ND (January 2010). "Weighing options for cancer risk reduction in carriers of BRCA1 and BRCA2 mutations". Journal of Clinical Oncology. 28 (2): 189–191. doi:10.1200/JCO.2009.25.6875. PMID 19996025.
Jeffers L, Reid J, Fitzsimons D, Morrison PJ, Dempster M (October 2019). "Interventions to improve psychosocial well-being in female BRCA-mutation carriers following risk-reducing surgery". The Cochrane Database of Systematic Reviews. 2019 (10): CD012894. doi:10.1002/14651858.cd012894.pub2. PMC 6784162. PMID 31595976.
King MC, Marks JH, Mandell JB (October 2003). "Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2". Science. 302 (5645): 643–646. Bibcode:2003Sci...302..643K. doi:10.1126/science.1088759. PMID 14576434. S2CID 33441900.
Huttley GA, Easteal S, Southey MC, Tesoriero A, Giles GG, McCredie MR, et al. (August 2000). "Adaptive evolution of the tumour suppressor BRCA1 in humans and chimpanzees. Australian Breast Cancer Family Study". Nature Genetics. 25 (4): 410–413. doi:10.1038/78092. PMID 10932184. S2CID 10004449.
Cook-Deegan R, DeRienzo C, Carbone J, Chandrasekharan S, Heaney C, Conover C (April 2010). "Impact of gene patents and licensing practices on access to genetic testing for inherited susceptibility to cancer: comparing breast and ovarian cancers with colon cancers". Genetics in Medicine. 12 (4 Suppl): S15–S38. doi:10.1097/GIM.0b013e3181d5a67b. PMC 3047448. PMID 20393305.
Benowitz S (January 2003). "European groups oppose Myriad's latest patent on BRCA1". Journal of the National Cancer Institute. 95 (1): 8–9. doi:10.1093/jnci/95.1.8. PMID 12509391.

ncbi.nlm.nih.gov

Petrucelli N, Daly MB, Pal T (September 1998). "BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer". In Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJ, Gripp KW, Amemiya A, editors (eds.). GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle. PMID 20301425.
Chen S, Parmigiani G (April 2007). "Meta-analysis of BRCA1 and BRCA2 penetrance". Journal of Clinical Oncology. 25 (11): 1329–1333. doi:10.1200/JCO.2006.09.1066. PMC 2267287. PMID 17416853.
Veronesi A, de Giacomi C, Magri MD, Lombardi D, Zanetti M, Scuderi C, et al. (July 2005). "Familial breast cancer: characteristics and outcome of BRCA 1-2 positive and negative cases". BMC Cancer. 5: 70. doi:10.1186/1471-2407-5-70. PMC 1184063. PMID 15996267.
Budroni M, Cesaraccio R, Coviello V, Sechi O, Pirino D, Cossu A, et al. (February 2009). "Role of BRCA2 mutation status on overall survival among breast cancer patients from Sardinia". BMC Cancer. 9: 62. doi:10.1186/1471-2407-9-62. PMC 2653541. PMID 19232099.
O'Malley DM, Krivak TC, Kabil N, Munley J, Moore KN (July 2023). "PARP Inhibitors in Ovarian Cancer: A Review". Targeted Oncology. 18 (4): 471–503. doi:10.1007/s11523-023-00970-w. PMC 10344972. PMID 37268756.
Kurian AW, Sigal BM, Plevritis SK (January 2010). "Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers". Journal of Clinical Oncology. 28 (2): 222–231. doi:10.1200/JCO.2009.22.7991. PMC 2815712. PMID 19996031.
Friedenson B (June 2005). "BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian". MedGenMed. 7 (2): 60. PMC 1681605. PMID 16369438.
Friedenson B (August 2007). "The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers". BMC Cancer. 7: 152. doi:10.1186/1471-2407-7-152. PMC 1959234. PMID 17683622.
Oktay K, Kim JY, Barad D, Babayev SN (January 2010). "Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks". Journal of Clinical Oncology. 28 (2): 240–244. doi:10.1200/JCO.2009.24.2057. PMC 3040011. PMID 19996028.
Moslehi R, Singh R, Lessner L, Friedman JM (March–April 2010). "Impact of BRCA mutations on female fertility and offspring sex ratio". American Journal of Human Biology. 22 (2): 201–205. doi:10.1002/ajhb.20978. PMC 3739697. PMID 19642207.
Agnese DM (March 2006). "Battle of the BRCA1/BRCA2 (offspring) sex ratios: truth or consequences". Journal of Medical Genetics. 43 (3): 201–202. doi:10.1136/jmg.2004.028977. PMC 2563236. PMID 16033919.
Kotsopoulos J, Lubinski J, Salmena L, Lynch HT, Kim-Sing C, Foulkes WD, et al. (March 2012). "Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers". Breast Cancer Research. 14 (2): R42. doi:10.1186/bcr3138. PMC 3446376. PMID 22405187.
Sawyer SL, Tian L, Kähkönen M, Schwartzentruber J, Kircher M, Majewski J, et al. (February 2015). "Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype". Cancer Discovery. 5 (2): 135–142. doi:10.1158/2159-8290.CD-14-1156. PMC 4320660. PMID 25472942.
Maxwell KN, Patel V, Nead KT, Merrill S, Clark D, Jiang Q, et al. (January 2023). "Fanconi anemia caused by biallelic inactivation of BRCA2 can present with an atypical cancer phenotype in adulthood". Clinical Genetics. 103 (1): 119–124. doi:10.1111/cge.14231. PMC 9742260. PMID 36089892.
Yoshida K, Miki Y (November 2004). "Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage". Cancer Science. 95 (11): 866–871. doi:10.1111/j.1349-7006.2004.tb02195.x. PMC 11159131. PMID 15546503. S2CID 24297965.
Cui J, Antoniou AC, Dite GS, Southey MC, Venter DJ, Easton DF, et al. (February 2001). "After BRCA1 and BRCA2-what next? Multifactorial segregation analyses of three-generation, population-based Australian families affected by female breast cancer". American Journal of Human Genetics. 68 (2): 420–431. doi:10.1086/318187. PMC 1235275. PMID 11133358.
Greenberg RA (September 2006). "BRCA mutations and childhood cancer". Cancer Biology & Therapy. 5 (9): 1103–1104. doi:10.4161/cbt.5.9.3370. PMC 2703724. PMID 17012842.
Rosenberg SM, Ruddy KJ, Tamimi RM, Gelber S, Schapira L, Come S, et al. (June 2016). "BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer". JAMA Oncology. 2 (6): 730–736. doi:10.1001/jamaoncol.2015.5941. PMC 5002892. PMID 26867710.
Kukafka R, Pan S, Silverman T, Zhang T, Chung WK, Terry MB, Fleck E, Younge RG, Trivedi MS, McGuinness JE, He T, Dimond J, Crew KD (18 July 2022). "Patient and Clinician Decision Support to Increase Genetic Counseling for Hereditary Breast and Ovarian Cancer Syndrome in Primary Care". JAMA Network Open. 5 (7). American Medical Association (AMA): e2222092. doi:10.1001/jamanetworkopen.2022.22092. ISSN 2574-3805. PMC 9294997.
Pijpe A, Andrieu N, Easton DF, Kesminiene A, Cardis E, Noguès C, et al. (September 2012). "Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK)". BMJ. 345: e5660. doi:10.1136/bmj.e5660. PMC 3435441. PMID 22956590.
Lynch HT, Casey MJ, Snyder CL, Bewtra C, Lynch JF, Butts M, Godwin AK (April 2009). "Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management". Molecular Oncology. 3 (2): 97–137. doi:10.1016/j.molonc.2009.02.004. PMC 2778287. PMID 19383374.
Pruthi S, Gostout BS, Lindor NM (December 2010). "Identification and Management of Women With BRCA Mutations or Hereditary Predisposition for Breast and Ovarian Cancer". Mayo Clinic Proceedings. 85 (12): 1111–1120. doi:10.4065/mcp.2010.0414. PMC 2996153. PMID 21123638.
Jeffers L, Reid J, Fitzsimons D, Morrison PJ, Dempster M (October 2019). "Interventions to improve psychosocial well-being in female BRCA-mutation carriers following risk-reducing surgery". The Cochrane Database of Systematic Reviews. 2019 (10): CD012894. doi:10.1002/14651858.cd012894.pub2. PMC 6784162. PMID 31595976.
Cook-Deegan R, DeRienzo C, Carbone J, Chandrasekharan S, Heaney C, Conover C (April 2010). "Impact of gene patents and licensing practices on access to genetic testing for inherited susceptibility to cancer: comparing breast and ovarian cancers with colon cancers". Genetics in Medicine. 12 (4 Suppl): S15–S38. doi:10.1097/GIM.0b013e3181d5a67b. PMC 3047448. PMID 20393305.

nihr.ac.uk

evidence.nihr.ac.uk

"Earlier decisions on breast and ovarian surgery reduce cancer in women at high risk". NIHR Evidence (Plain English summary). National Institute for Health and Care Research. 7 December 2021. doi:10.3310/alert_48318. S2CID 263487127.

nytimes.com

Schwartz J (12 May 2009). "Cancer Patients Challenge the Patenting of a Gene". The New York Times.
Liptak A (13 June 2013). "Supreme Court Rules Human Genes May Not Be Patented". The New York Times. Retrieved 13 June 2013.

ornl.gov

"Genetics and Patenting". Human Genome Project Information. U.S. Department of Energy Genome Programs. 7 July 2010.

patents.google.com

semanticscholar.org

api.semanticscholar.org

Verhoog LC, Brekelmans CT, Seynaeve C, van den Bosch LM, Dahmen G, van Geel AN, et al. (January 1998). "Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1". Lancet. 351 (9099): 316–321. doi:10.1016/S0140-6736(97)07065-7. PMID 9652611. S2CID 38655517.
Fishman A (October 2010). "The effects of parity, breastfeeding, and infertility treatment on the risk of hereditary breast and ovarian cancer: a review". International Journal of Gynecological Cancer. 20 (11 Suppl 2): S31–S33. doi:10.1111/IGC.0b013e3181f60d4d. PMID 20975359. S2CID 42755864.
Balmaña J, Díez O, Campos B, Majewski M, Sanz J, Alonso C, et al. (August 2005). "Sex ratio distortion in offspring of families with BRCA1 or BRCA2 mutant alleles: an ascertainment bias phenomenon?". Breast Cancer Research and Treatment. 92 (3): 273–277. doi:10.1007/s10549-005-3377-x. PMID 16155798. S2CID 21830848.
Yoshida K, Miki Y (November 2004). "Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage". Cancer Science. 95 (11): 866–871. doi:10.1111/j.1349-7006.2004.tb02195.x. PMC 11159131. PMID 15546503. S2CID 24297965.
Cibula D, Zikan M, Dusek L, Majek O (August 2011). "Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis". Expert Review of Anticancer Therapy. 11 (8): 1197–1207. doi:10.1586/era.11.38. PMID 21916573. S2CID 31012428.
Kwon JS, Tinker A, Pansegrau G, McAlpine J, Housty M, McCullum M, Gilks CB (January 2013). "Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers". Obstetrics and Gynecology. 121 (1): 14–24. doi:10.1097/AOG.0b013e3182783c2f. PMID 23232752. S2CID 41081248.
"Earlier decisions on breast and ovarian surgery reduce cancer in women at high risk". NIHR Evidence (Plain English summary). National Institute for Health and Care Research. 7 December 2021. doi:10.3310/alert_48318. S2CID 263487127.
Marcinkute R, Woodward ER, Gandhi A, Howell S, Crosbie EJ, Wissely J, et al. (February 2022). "Uptake and efficacy of bilateral risk reducing surgery in unaffected female BRCA1 and BRCA2 carriers". Journal of Medical Genetics. 59 (2): 133–140. doi:10.1136/jmedgenet-2020-107356. PMID 33568438. S2CID 231876899.
King MC, Marks JH, Mandell JB (October 2003). "Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2". Science. 302 (5645): 643–646. Bibcode:2003Sci...302..643K. doi:10.1126/science.1088759. PMID 14576434. S2CID 33441900.
Huttley GA, Easteal S, Southey MC, Tesoriero A, Giles GG, McCredie MR, et al. (August 2000). "Adaptive evolution of the tumour suppressor BRCA1 in humans and chimpanzees. Australian Breast Cancer Family Study". Nature Genetics. 25 (4): 410–413. doi:10.1038/78092. PMID 10932184. S2CID 10004449.

uptodate.com

Iodice S, Barile M, Rotmensz N, Feroce I, Bonanni B, Radice P, et al. (August 2010). "Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis". European Journal of Cancer. 46 (12): 2275–2284. doi:10.1016/j.ejca.2010.04.018. PMID 20537530.
Lu KH, Berchuck A, Kauff ND (2013). "Hereditary gynecologic cancers". In Barakat RD, Berchuck A, Markman M, Randall ME (eds.). Principles and practice of gynecologic oncology (6th ed.). Philadelphia: Lippincott Williams & Wilkins. ISBN 978-1-4698-3148-0.
Isaacs C, Fletcher SW, Peskin BN (May 2013). Hayes DF, Duda RB (eds.). "Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations". Waltham, Mass.: UpToDate. Retrieved 13 June 2013.
PDQ Cancer Genetics Editorial Board (7 June 2013). "PDQ Genetics of breast and ovarian cancer (Health professional version)". Bethesda, Md.: National Cancer Institute. Retrieved 13 June 2013.

web.archive.org

Myriad Investor Page—see "Myriad at a glance" Archived 18 October 2012 at the Wayback Machine accessed October 2012
"ACLU sues over patents on breast cancer genes". CNN. Archived from the original on 15 May 2009. Retrieved 14 May 2009.

worldcat.org

Kukafka R, Pan S, Silverman T, Zhang T, Chung WK, Terry MB, Fleck E, Younge RG, Trivedi MS, McGuinness JE, He T, Dimond J, Crew KD (18 July 2022). "Patient and Clinician Decision Support to Increase Genetic Counseling for Hereditary Breast and Ovarian Cancer Syndrome in Primary Care". JAMA Network Open. 5 (7). American Medical Association (AMA): e2222092. doi:10.1001/jamanetworkopen.2022.22092. ISSN 2574-3805. PMC 9294997.